Drug Profile
LBT 811
Alternative Names: LBT811Latest Information Update: 12 May 2021
Price :
$50
*
At a glance
- Originator Cyclopharma
- Developer Zionexa
- Class Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 06 May 2021 Zionexa has been acquired by GE Healthcare
- 28 Aug 2019 No recent reports of development identified for clinical-Phase-Unknown development in Neurological-disorders(Diagnosis) in France (Parenteral)
- 08 Jul 2016 Clinical trials in Neurological disorders (Diagnosis) in France (Parenteral)